Findings

What do systematic reviews say?

78 questions · 78 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 16 · 20.5%GRADE not reported 15 · 19.2%Very low 24 · 30.8%Low 12 · 15.4%Moderate 11 · 14.1%High 0 · 0%

Deferasirox vs combined deferasirox and deferiprone

Mortality at any time point · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Responder analysis · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Serum ferritin (ng/mL) · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

LIC · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Satisfaction with treatment · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Adherence · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

AE: Serum creatinine increase · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs deferoxamine

Mortality at any time point · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in mortality at any time point compared with deferoxamine (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.48 [0.09, 2.63]
8 studies · 1170 participants
Low

Deferasirox vs deferiprone

Serum ferritin (ng/mL): mean change from baseline and at end of study · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Very low

Deferasirox vs deferiprone

LIC · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Deferasirox vs deferiprone

Satisfaction · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: discontinuations compared with deferiprone (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
3 studies · 179 participants
Low

Deferasirox vs deferiprone

Renal failure · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Deferasirox vs deferoxamine

Responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw) · people with transfusion‐dependent thalassemia

Deferasirox probably leads to lower responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw) compared with deferoxamine (moderate certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.8 [0.69, 0.92]
1 study · 553 participants
Moderate

Deferasirox vs deferoxamine

Serum ferritin (ng/mL): mean change from baseline and at end of study · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1002 participants
Moderate

Deferasirox vs deferoxamine

Change in LIC (mg Fe/g dw) evaluated by biopsy or SQUID · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 541 participants
Moderate

Deferasirox vs placebo

Mortality at any time point · people with non‐transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 148 participants
Moderate

Deferasirox vs placebo

Responder analysis · people with non‐transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs placebo

Serum ferritin (ng/mL): mean change from baseline · people with non‐transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 154 participants
Moderate

Deferasirox vs placebo

LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline · people with non‐transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 159 participants
Moderate